Background: Taurine (2-aminoethanesulfonic acid) is a semi-essential amino acid found in mammalian tissues that is not involved in protein synthesis. The function of taurine is not completely understood. Some studies have demonstrated that taurine supplementation reduces death rate in rabbits with heart failure (HF) and diminishes HF severity in human models of congestive HF. In this study we have evaluated the effect of taurine supplementation on exercise capacity of patients with HF. Methods: A randomized single-blind placebo-controlled clinical trial was conducted on 29 patients with HF with left ventricular ejection fraction (LVEF) less than 50% who were in functional class II or III according to New York Heart Association classification. A total of 15 patients received taurine supplementation 500 mg three times a day while the remaining 14 patients received placebo for 2 weeks. All patients performed exercise tolerance test before and after taurine and placebo supplementation. 
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Results: The mean age of patients was 60.57 ± 6.54 years, they were mostly male (26 of 29), and had mean LVEF of 29.27 ± 6.97%. There were no significant differences in terms of LVEF, body mass index, and also exercise time, metabolic equivalents (METS) and exercise distance before supplementation. Exercise time, METS, and exercise distance increased significantly in patients who received taurine supplement for 2 weeks (p-value < 0.0001 for all), but did not increase significantly in patients who received placebo (p-values 0.379, 0.244, and 0.577 respectively). Conclusion: Taurine supplementation in patients with HF who are taking standard medical treatment can increase their exercise capacity. © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Background
Taurine (2-aminoethanesulfonic acid) is a semi-essential amino acid found in mammalian tissues that is not involved in protein synthesis and is the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes [1] . Taurine's function is not understood completely but some cellular osmoregulations are modulated by taurine [2, 3] . It has been demonstrated in vitro in various species that low levels of taurine are associated with various pathological lesions, including cardiomyopathy [4] .
Taurine has been used in experimental and clinical studies for treating several cardiovascular diseases including hypertension, hypercholesterolemia, atherosclerosis, cardiomyopathy, and congestive heart failure (CHF) [2, [5] [6] [7] .
In experimental CHF in dogs [8] and rabbits [9] increasing taurine levels in heart have been shown, as in left ventricular muscle of patients who had died of CHF [10] .
Some studies have demonstrated that taurine supplementation reduces death rate in rabbits with heart failure (HF) [9] and diminishes HF severity in human models of CHF [11] .
In this study we have evaluated the effect of taurine supplementation on exercise capacity of patients with HF.
Methods
A randomized single-blind placebo-controlled clinical trial approved by the ethics committee of Shahid Beheshti Medical University was executed in accordance with the Declaration of Helsinki in Loghman Hakim Hospital in Tehran, Iran in 2008. After obtaining their informed consents, 29 patients with HF due to coronary heart disease with left ventricle ejection fraction (LVEF) less than 50% who were in functional class II or III according to New York Heart Association (NYHA) classification were randomized to four groups (Table 1) : seven patients who received taurine supplementation (Taurine capsule, Solgar, Leonia, NJ, USA) 500 mg three times a day for 2 weeks and performed exercise tolerance test (ETT) with Bruce protocol before and after taurine supplementation; eight patients received taurine and performed ETT with modified Bruce protocol; and six and eight patients received placebo (starch) and performed ETT with Bruce and modified Bruce protocols, respectively.
NDrug history, electrocardiogram characteristics, heart rates (HR) and blood pressures (BP) of patients were recorded before ETT and then a 10-mL blood sample was taken for measuring taurine serum levels by high performance liquid chromatography (HPLC) method. In addition to the usual parameters of ETT, metabolic equivalents (METS) and distances patients had covered were recorded. After 2 weeks of supplementation, all of these parameters were measured again. We used chi-square tests (Fisher's exact test where applicable) for categorical variables and ANOVA and Tukey's tests for quantitative variables to analyze our data. A p-value less than 0.05 was considered statistically significant. SPSS 13.0 for Windows (SPSS, Inc., Chicago, IL, USA) was used for all statistical tests.
Results
The patients had a mean age of 60.57 ± 6.54 (50-65 years) years, were mostly male (26 of 29) and had mean LVEF of 29.27 ± 6.97%. There were no significant differences in terms of LVEF, body mass index (BMI) and also exercise time, METS and exercise distance before supplementation (Table 2) . Drug history regarding use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, aspirin, statins, diuretics, and nitrates before and after supplementation was not significantly different between groups with taurine supplement and placebo supplement (p-values were 0.876, 0.483, 0.33 0.483, 0.10, 0.191, and 1, respectively).
Exercise time, METS, and exercise distance in group 1 (taurine -Bruce) increased significantly (p-values were 0.022, 0.043, and 0.012, respectively).
In group 2 (taurine -modified Bruce) also, exercise time, METS, and exercise distance increased significantly (p-values were 0.000, 0.001, and 0.003, respectively).
Exercise time, METS, and exercise distance were increased significantly in all of 15 patients who received taurine supplement (group 1 + group 2) after 2 weeks (pvalues < 0.0001 for all).
In group 3 (placebo -Bruce), exercise time, METS, and exercise distance did not increase significantly (p-values were 0.264, 0.057, and 0.099, respectively).
Exercise time and exercise distance did not increase significantly (p-values were 0.155 and 0.071, respectively) in group 4 (placebo -modified Bruce), but METS increased significantly (p-value = 0.029).
All of these parameters did not increase significantly in all of 14 patients (group 3 + group 4) who did not receive taurine supplementation (p-values were 0.379, 0.244, and 0.577) ( Table 3 ).
Discussion
This study shows that taurine supplementation 500 mg three times a day in patients with HF in NYHA class II or III, who were on medical treatment, increased exercise time, METS, T, taurine; B, Bruce protocol; P, placebo; MB, modified Bruce protocol; BMI, body mass index; EF, ejection fraction; BP blood pressure; sys, systolic; dias, diastolic; HR, heart rate; Ex, exercise; METS, metabolic equivalents; 1 = before supplementation; 2 = after supplementation. and exercise distance. Animal studies demonstrate that taurine supplementation prevents or slows HF development, reduces mortality, and hence improves survival [12] [13] [14] . However, in humans, there is paucity of data on assessment of taurine effects on HF. Azuma et al. showed that taurine supplementation with a dose of 2 g BID for 4 or 8 weeks in 24 patients with CHF improved their clinical situations and NYHA functional class [11] . In a double-blind crossover trial on 14 patients with CHF, Azuma et al. demonstrated that taurine supplementation for a 4-week period improved NYHA functional class, pulmonary crackles, and chest film abnormalities in comparison with placebo [15] . In another study Azuma et al. evaluated the effect of oral administration of taurine (3 g/day) and coenzyme Q10 (CoQ10) (30 mg/day) in 17 patients with CHF secondary to ischemic or idiopathic dilated cardiomyopathy with LVEF less than 50% and showed significant improvement in LV systolic function after 6 weeks [16] .
The positive effects of taurine on LV function may be due to its regulatory role in intracellular Ca 2+ homeostasis via its effect on voltage-dependent Ca 2+ channels, by regulation of Na+ channels, and via Na-Ca exchange and Na(+)-taurine cotransport [17, 18] . Hence taurine modulates intracellular Ca 2+ levels. Taurine also has a potent antioxidant role that may contribute to its potential benefits in patients with HF [19] . The failing myocardium exhibits increased intracellular and mitochondrial calcium, which results in a decrease in myocardial energy production and an increase in oxidative stress [20] . Taurine has many other effects on the cardiovascular system including its beneficial impact on macrovascular endothelial function [21] that may have some speculative role in patients with HF.
To the best of our knowledge, our study is the first clinical trial that specifically assesses the effect of taurine supplementation on exercise capacity of patients with HF and is compatible with other studies that have shown a positive effect of taurine on patients with HF.
Limitations of this study include small size of the sample, single-blind study and lack of repetition of echocardiography after supplementation.
Conclusion
Taurine supplementation in patients with CHF who are taking standard medical treatment can increase their exercise capacity.
